Good public speaker but that is it...not a fan. I believe in long term solutions and not giving everything away..hard work makes a good american.
boost to Sarepta or they think as themselves as a legend in their own mind.
This is a message board not a newspaper and yes i love this sarepta science .if one understands the science it makes them more inclined to be bullish much more than others..your opinion of me does not matter one once compared to my confidence of 25 years of research history.
Really really soon.
with a share swap or another large Pharma?
Would be crazy for them not to try....
The new guidance takes into consideration increased risk tolerance among some DMD patients involved in trials. Acceptable endpoints may now include functional, cardiac, or respiratory metrics, though the FDA has asserted that the ideal trial design still involves a randomized, placebo-controlled design—even if the placebo-controlled part involves using historical data.
Sarepta will be the drug of choice..does not matter if drisa is approved it will be a big back seat to Sarepta's dmd drugs ..the end
very good future for GILD
Every analyst has estimates and the post was intended to spark details and not replies that try to be a '' want-t0-be-message board correctional officer expert about non-pertaining answers.